(STAT) The curious relationship between one of the world’s biggest drug makers and President Trump’s personal lawyer began early last year.
That’s when Michael Cohen, a longtime fixer for the president, reached out to Novartis’s then-chief executive officer Joe Jimenez, promising help gaining access to Trump and influential officials in the new administration, according to an employee inside Novartis familiar with the matter.
Jimenez took the call and then instructed his team to reach a deal with Cohen. A one-year contract worth $1.2 million was signed with Cohen in February 2017.
The company’s hope was that Cohen could help it navigate a bevy of uncertain issues facing the drug maker — from potential changes to the Affordable Care Act and tax reform to navigating reimbursement challenges for medicines.
“He reached out to us,” the Novartis employee said, providing STAT with the company’s version of events as it scrambles to contain the fallout from being entangled in the investigations surrounding Trump and his inner circle, including Cohen.
“With a new administration coming in, basically, all the traditional contacts disappeared and they were all new players. We were trying to find an inroad into the administration. Cohen promised access to not just Trump, but also the circle around him. It was almost as if we were hiring him as a lobbyist.”
In March 2017, a group of Novartis employees, mostly from the government affairs and lobbying teams, met with Cohen in New York to discuss specific issues and strategies.
But the meeting was a disappointment, the insider explained, and the Novartis squad left with the impression that Cohen and Essential Consultants — the firm controlled by Cohen that Novartis was making payments to — may not be able to deliver. Read the full story at STAT. IMAGE: Andrew Hecht, CC BY 2.0;
Michael Vadon, CC BY-SA 4.0